BioXcel Therapeutics Inc (BTAI) FinancialsBTAIBioXcel Therapeutics Inc

Evaluating the bottom line, BioXcel Therapeutics Inc maintains a gross margin of 87.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5600.55%, while the net margin is -8084.07%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BTAI converts its operational activities into shareholder value.

In the context of the broader market, BTAI competes directly with industry leaders such as OGCP and CHGA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BTAI's gross margin of 87.91% stands against OGCP's N/A and CHGA's N/A. Such benchmarking helps identify whether BioXcel Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown a troubling trend with a net income loss of $14,713,000 in Q2 2026 and a current ratio of only 0.21, indicating liquidity issues. Total revenue has been inconsistent, with a peak of $366,000 in Q4 2024, but recent quarters have shown declining revenues.